We are faced with a global pandemic of tuberculosis and new tools to control this disease are needed urgently. We believe that new drugs are central to any control strategy and the fastest route to tuberculosis elimination.
The consortium brings together a group of scientists from more that 14 countries with skills in clinical trials, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service.
In 2003 the European Developing Clinical Trial Partnership (EDCTP) was founded as a European Economic Interest Group by the European member states and the European Commission. When created, its target was poverty-related disease (HIV/AIDS, malaria and tuberculosis and focusing on phase II and III clinical trials). EDCTP was intended to be a platform where countries…
PanACEA II is a network of presently 5 European and 11 African institutions who share the common vision of developing ground-breaking strategies in TB drug development. PanACEA II is coordinated from Radboudumc Nijmegen. The partners from the consortium meet at a mimimum once per year face to face and have frequent exchange through teleconferences, emails and intranet. The PanACEA secretariat is…
European & Developing Countries Clinical Trials Partnership (EDCTP) The EDCTP programme is supported under Horizon 2020, the European Union’s Framework Programme for Research and Innovation Bundesministerium für Bildung und Forschung (BMBF) Switzerland secretariat for Education, Research and Innovation SERI
We have no employment opportunities at present.
Building on its vast experience across its African and European member institutions and networking with key players across the globe, PanACEA boosts innovative research on TB drug development.
